STAT+: Novo Nordisk’s obesity drug Wegovy cleared to treat MASH
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.
Previous Post
Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC
Next Post
Medical cannabis has a high discontinuation rate for treatment of musculoskeletal pain
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago